These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12744901)

  • 41. [Measles seroprevalence in the schoolchildren of Valencia. The Measles Study Group].
    Díez Domingo J; Calvo Rigual F; González Granda D
    Med Clin (Barc); 1995 Oct; 105(13):487-90. PubMed ID: 7494436
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nonclassic measles infections in an immune population exposed to measles during a college bus trip.
    Helfand RF; Kim DK; Gary HE; Edwards GL; Bisson GP; Papania MJ; Heath JL; Schaff DL; Bellini WJ; Redd SC; Anderson LJ
    J Med Virol; 1998 Dec; 56(4):337-41. PubMed ID: 9829639
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Measles epidemiology and the status of specific immunity in Novgorod Province during a mass immunization].
    Golubeva LI; Brantseva IV
    Tr Inst Im Pastera; 1985; 62():68-72. PubMed ID: 2954277
    [No Abstract]   [Full Text] [Related]  

  • 44. Evaluation of maternal measles antibody titers and response to the measles vaccination at the age of 9 months in preterm infants.
    Ozturk S; Kavuncuoglu S; Ozbek S; Vural M
    Eur J Pediatr; 2007 Nov; 166(11):1181-2. PubMed ID: 17136351
    [No Abstract]   [Full Text] [Related]  

  • 45. Measles antibody response in vaccinated children.
    Evliyaoğlu N; Altintaş D; Kiliç NB; Alhan SE; Onenli N; Güneşer S; Bahçebaşi T
    Turk J Pediatr; 1996; 38(3):315-21. PubMed ID: 8827900
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The sero-epidemiology of measles in children from Eastern Turkey.
    Altinkaynak S; Ertekin V; Güraksin A; Kiliç A; Yiğit N
    West Indian Med J; 2005 Sep; 54(4):236-7. PubMed ID: 16312189
    [No Abstract]   [Full Text] [Related]  

  • 47. Impact of a measles outbreak response immunization campaign: Maroua, Cameroon, 2009.
    Goodson JL; Sosler S; Pasi O; Johnson T; Kobella M; Monono ME; Uzicanin A
    J Infect Dis; 2011 Jul; 204 Suppl 1():S252-9. PubMed ID: 21666170
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Maintaining high rates of measles immunization in Africa.
    Lessler J; Moss WJ; Lowther SA; Cummings DA
    Epidemiol Infect; 2011 Jul; 139(7):1039-49. PubMed ID: 20920382
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The epidemiological efficacy of mass vaccination against measles among the troops].
    Sibilev VI; Shevtsova VA; Tiasto EA
    Voen Med Zh; 1994 Feb; (2):50-1, 80. PubMed ID: 8165796
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Measles at the point of being eliminated].
    De Ory F; Peña-Rey I
    Enferm Infecc Microbiol Clin; 2010 Feb; 28(2):73-4. PubMed ID: 20096973
    [No Abstract]   [Full Text] [Related]  

  • 51. Prevalence of measles antibody in children of different ages in Shiraz, Islamic Republic of Iran.
    Karimi A; Arjomandi A; Alborzi A; Rasouli M; Kadivar MR; Obood B; Pourabbas B
    East Mediterr Health J; 2004; 10(4-5):468-73. PubMed ID: 16335636
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Measles Cases during Ebola Outbreak, West Africa, 2013-2106.
    Colavita F; Biava M; Castilletti C; Quartu S; Vairo F; Caglioti C; Agrati C; Lalle E; Bordi L; Lanini S; Guanti MD; Miccio R; Ippolito G; Capobianchi MR; Di Caro A;
    Emerg Infect Dis; 2017 Jun; 23(6):1035-1037. PubMed ID: 28518027
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predicting the impact of measles vaccination in England and Wales: model validation and analysis of policy options.
    Babad HR; Nokes DJ; Gay NJ; Miller E; Morgan-Capner P; Anderson RM
    Epidemiol Infect; 1995 Apr; 114(2):319-44. PubMed ID: 7705494
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Kinetics of decline of maternal measles virus-neutralizing antibodies in sera of infants in France in 2006.
    Gagneur A; Pinquier D; Aubert M; Balu L; Brissaud O; De Pontual L; Gras Le Guen C; Hau-Rainsard I; Mory O; Picherot G; Stephan JL; Cohen B; Caulin E; Soubeyrand B; Reinert P
    Clin Vaccine Immunol; 2008 Dec; 15(12):1845-50. PubMed ID: 18815232
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Antibodies to measles virus in blood sera of individuals who were not verified as having been infected with the virus (years 1984-1989)].
    Gut W; Litwińska B
    Przegl Epidemiol; 1991; 45(3):147-56. PubMed ID: 1819809
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Measles seroepidemiology among adolescents and young adults: response to revaccination.
    Saffar MJ; Alraza-Amiri M; Ajami A; Baba-Mahmoodi F; Khalilian AR; Vahidshahi C; Shamsizadeh A
    East Mediterr Health J; 2006 Sep; 12(5):573-81. PubMed ID: 17333796
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modeling the impact of subclinical measles transmission in vaccinated populations with waning immunity.
    Mossong J; Nokes DJ; Edmunds WJ; Cox MJ; Ratnam S; Muller CP
    Am J Epidemiol; 1999 Dec; 150(11):1238-49. PubMed ID: 10588085
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Estimating the Number of Measles-Susceptible Children and Adolescents in the United States Using Data From the National Immunization Survey-Teen (NIS-Teen).
    Bednarczyk RA; Orenstein WA; Omer SB
    Am J Epidemiol; 2016 Jul; 184(2):148-56. PubMed ID: 27338281
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Persistence of vaccine-induced antibody to measles 26-33 years after vaccination.
    Dine MS; Hutchins SS; Thomas A; Williams I; Bellini WJ; Redd SC
    J Infect Dis; 2004 May; 189 Suppl 1():S123-30. PubMed ID: 15106101
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Measles antibody prevalence after mass immunization campaign in Niterói, state of Rio de Janeiro, Brazil.
    Oliveira SA; Siqueira MM; Mann GF; Costa AJ; Almeida MT; Stavola MS; Tomasini H; Nascimento JP
    Rev Inst Med Trop Sao Paulo; 1996; 38(5):355-8. PubMed ID: 9293077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.